Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792226 | 0.98 | PPARA (0.61) | PPARACA2CA1CA12CA7 | |
| SCHEMBL3787719 | 0.98 | PPARA (0.61) | PPARACA2CA1CA12CA7 | |
| SCHEMBL1668207 | 0.98 | PPARA (0.61) | PPARACA2CA1CA12CA7 | |
| SCHEMBL56009 | 0.98 | PPARA (0.61) | PPARACA2CA1CA12CA7 | |
| SCHEMBL3794667 | 0.98 | PPARA (0.61) | PPARACA2CA1CA12CA7 | |
| SCHEMBL291896 | 0.98 | PPARA (0.61) | PPARACA2CA1CA12CA7 | |
| SCHEMBL4622860 | 0.98 | PPARA (0.61) | PPARACA2CA1CA12CA7 | |
| SCHEMBL41855 | 0.92 | — | — | |
| SCHEMBL42317 | 0.81 | — | — | |
| SCHEMBL4563383 | 0.79 | PPARA (0.86) | PPARACA2CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153515-A1 | COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AB Pharma Ltd (CN) | 2017-04-12 | — | — | EP | claimed |
| US-8815796-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-08-26 | — | — | US | claimed |
| US-8653025-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-02-18 | — | — | US | claimed |
| US-20140005104-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2014-01-02 | — | — | US | claimed |
| EP-2528922-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd (CN) | 2012-12-05 | — | — | EP | claimed |
| CN-102498101-A | Aniline compounds | UBE INDUSTRIES | 2012-06-13 | — | — | CN | claimed |
| WO-2011091757-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-08-04 | — | — | WO | claimed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | claimed |
| WO-2010012793-A1 | FUNGICIDE AMINOTHIAZOLE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2010-02-04 | — | — | WO | claimed |
| EP-1558253-A4 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1100506-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2001-05-23 | — | — | EP | claimed |
| EP-0934305-A4 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2001-04-11 | — | — | EP | claimed |
| WO-2000078317-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | claimed |
| EP-1040111-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | claimed |
| WO-2000006169-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-02-10 | — | — | WO | claimed |
| EP-0934305-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1999031099-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | claimed |
| WO-1998008840-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-03-05 | — | — | WO | claimed |
| US-5426022-A | Silver halide emulsion layer, a color copler and a ultraviolet radiation stabilizer; used for colorphotography | AGFA-GEVAERT AG (DE) | 1995-06-20 | — | — | US | claimed |
| US-5306609-A | With nondiffusive coupler and acyl acetamide coupler of specified formulae; high color density, color image fastness | FUJI PHOTO FILM CO., LTD. (JP) | 1994-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005104-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | PPARA 2944/4885CA2 4144/4885CA1 3729/4885 |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | PPARA 2944/4885CA2 4144/4885CA1 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.